Our achievements. Our accomplishments. Our impact.



  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Career Development

    The multidisciplinary research and training program offered by the Stem Cell Network enriched and accelerated the careers of hundreds of young researchers, many of whom can now be found across industry, government and academia.

    READ STORY

  • Clinical Trials

    When the Stem Cell Network was first funded, its leadership considered that catalyzing a single clinical trial during its 14-year mandate would have been a success. Instead, the Network’s research investments have led to 12 clinical trials on various diseases, with even more in the development pipeline.

    READ STORY

  • Till & McCulloch Meetings

    The Stem Cell Network’s Annual General Meeting, which metamorphosed into the Till & McCulloch Meetings, is a one-of-a-kind venue for trainees and young scientists to network and gain experience in the competitive field of regenerative medicine.

    READ STORY

  • Catalyzing New Organizations

    The Stem Cell Network was critical for strategically identifying structural gaps in the Canadian stem cell research landscape and bringing together diverse stakeholder groups to seize those opportunities through the incubation and launch of new organizations.

    READ STORY

  • Blood Stem Cell Expansion

    Over more than a decade of targeted funding, the Stem Cell Network harnessed the strength of world-leading Canadian researchers to develop technologies to increase quantities of blood stem cells for expanded therapeutic use and to overcome a significant hurdle in the delivery of cell-based treatments to patients.

    READ STORY